Protagonist Therapeutics (PTGX) Long-Term Deferred Tax (2018 - 2020)

Protagonist Therapeutics has disclosed Long-Term Deferred Tax across 3 years of filings, most recently posting $1.1 million for Q1 2020.

• Long-Term Deferred Tax for Q1 2020 came in at $1.1 million, up 126.36% year-over-year; the trailing twelve-month figure through Mar 2020 was $1.1 million (up 126.36% YoY), and the FY2019 annual result was $1.4 million, up 117.78% from the prior year.
• Long-Term Deferred Tax came in at $1.1 million for Q1 2020 at Protagonist Therapeutics, down from $1.4 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $2.1 million in Q3 2019 to a low of $478000.0 in Q1 2019.
• The 3-year median for Long-Term Deferred Tax is $1.3 million (2019), against an average of $1.3 million.
• Across the five-year window, Long-Term Deferred Tax soared 117.78% in 2019 and jumped 126.36% in 2020, its largest moves.
• Protagonist Therapeutics' Long-Term Deferred Tax stood at $658000.0 in 2018, then jumped by 117.78% to $1.4 million in 2019, then decreased by 24.49% to $1.1 million in 2020.
• The last three Long-Term Deferred Tax figures came in at $1.1 million (Q1 2020), $1.4 million (Q4 2019), and $2.1 million (Q3 2019), per Business Quant data.